{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:55:45Z","timestamp":1794621345173,"version":"4.9.1"},"reference-count":43,"publisher":"American Association for Cancer Research (AACR)","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA281980-01"],"award-info":[{"award-number":["1R01CA281980-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA262028-01A1"],"award-info":[{"award-number":["1R01CA262028-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Antibody\u2013drug conjugate (ADC) represents an effective therapeutic strategy for cancer, leveraging a cancer-targeting monoclonal antibody (mAb) linked to a potent payload. In this study, we report novel dual-payload ADCs (DualADC), which harness one antibody to simultaneously deliver chemotherapy and immunotherapy for aggressive triple-negative breast cancer (TNBC). Specifically, we developed two-site, that is, cysteine and lysine, co-conjugation technologies to link a chemotherapeutic agent for direct tumor cell killing and a Toll-like receptor dual agonist for tumoral immunity enhancement to our humanized anti-CD276 (B7-H3) mAb. Our antibody binds to TNBC with high affinity and selectivity while exhibiting minimal off-target effects in normal human tissues. Three DualADCs were fully characterized by validating the conjugations and quantifying the drug-to-antibody ratios and drug-to-drug ratio using several analytic tools. In vitro evaluations revealed a high cancer cell binding rate via flow cytometry, efficient drug internalization with confocal microscopy, and high anticancer cytotoxicity in three TNBC cell lines. In vivo investigations in two TNBC xenograft mouse models demonstrated that DualADC carrying deruxtecan and imidazoquinoline has the best antitumor efficacy, that is, favorable biodistribution in TNBC, high tumor burden reduction, low systemic toxicity, and upregulation of immune pathways. Collectively, this study establishes advanced dual-payload antibody\u2013drug conjugation technologies and identifies a good DualADC candidate for cancer therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Advanced dual-payload antibody-drug conjugation technologies were established, and a promising DualADC was developed for targeted cancer chemoimmunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0059","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:02:51Z","timestamp":1776798171000},"page":"898-912","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advanced CD276-Targeting Dual-Payload Antibody\u2013Drug Conjugates for Cancer Therapy"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2669-9595","authenticated-orcid":false,"given":"Zhuoxin","family":"Zhou","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 1 Department of Chemical and Biomolecular Engineering, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4277-6468","authenticated-orcid":false,"given":"Davis","family":"Ballard","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 1 Department of Chemical and Biomolecular Engineering, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8953-8963","authenticated-orcid":false,"given":"Jiashuai","family":"Zhang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 2 Department of Biomedical Engineering, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3321-2634","authenticated-orcid":false,"given":"Zhantao","family":"Du","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 1 Department of Chemical and Biomolecular Engineering, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3573-2223","authenticated-orcid":false,"given":"Natsorn","family":"Watcharadulyarat","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 1 Department of Chemical and Biomolecular Engineering, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7235-1414","authenticated-orcid":false,"given":"Tanvi","family":"Varadkar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 1 Department of Chemical and Biomolecular Engineering, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-984X","authenticated-orcid":false,"given":"Srijita","family":"Chowdhury","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 1 Department of Chemical and Biomolecular Engineering, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2123-2364","authenticated-orcid":false,"given":"Sathvik R.","family":"Kambam","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 1 Department of Chemical and Biomolecular Engineering, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1465-2217","authenticated-orcid":false,"given":"Phoebe","family":"Hu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 1 Department of Chemical and Biomolecular Engineering, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1054-4426","authenticated-orcid":false,"given":"Selena","family":"Khanal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 1 Department of Chemical and Biomolecular Engineering, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1321-8442","authenticated-orcid":false,"given":"Lufang","family":"Zhou","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 2 Department of Biomedical Engineering, , Columbus, Ohio."},{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 3 Department of Surgery, , Columbus, Ohio."},{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 4 The James Comprehensive Cancer Center, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4617-9750","authenticated-orcid":false,"given":"Xiaoguang","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 1 Department of Chemical and Biomolecular Engineering, , Columbus, Ohio."},{"id":[{"id":"https:\/\/ror.org\/00rs6vg23","id-type":"ROR","asserted-by":"publisher"}],"name":"The Ohio State University 4 The James Comprehensive Cancer Center, , Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2026042115023971300_bib1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026042115023971300_bib2","first-page":"187","article-title":"The advance of adjuvant treatment for triple-negative breast cancer","volume":"19","author":"Ge","year":"2021","journal-title":"Cancer Biol Med"},{"key":"2026042115023971300_bib3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple-negative breast cancer therapy: current and future perspectives (Review)","volume":"57","author":"Won","year":"2020","journal-title":"Int J Oncol"},{"key":"2026042115023971300_bib4","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026042115023971300_bib5","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","article-title":"Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer","volume":"28","author":"Silver","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026042115023971300_bib6","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/cells8090957","article-title":"Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge","volume":"8","author":"Nedeljkovi\u0107","year":"2019","journal-title":"Cells"},{"key":"2026042115023971300_bib7","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.breast.2017.06.023","article-title":"Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC)","volume":"34 Suppl 1","author":"Wein","year":"2017","journal-title":"Breast"},{"key":"2026042115023971300_bib8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","article-title":"Eradication of tumors through simultaneous ablation of CD276\/B7-H3-positive tumor cells and tumor vasculature","volume":"31","author":"Seaman","year":"2017","journal-title":"Cancer Cell"},{"key":"2026042115023971300_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/elsc.202000027","article-title":"Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy","volume":"21","author":"Si","year":"2021","journal-title":"Eng Life Sci"},{"key":"2026042115023971300_bib10","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1002\/mco2.671","article-title":"Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies","volume":"5","author":"He","year":"2024","journal-title":"MedComm (2020)"},{"key":"2026042115023971300_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12272-023-01479-6","article-title":"Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions","volume":"47","author":"Kumari","year":"2024","journal-title":"Arch Pharm Res"},{"key":"2026042115023971300_bib12","doi-asserted-by":"crossref","first-page":"2229101","DOI":"10.1080\/19420862.2023.2229101","article-title":"Exploration of the antibody-drug conjugate clinical landscape","volume":"15","author":"Maecker","year":"2023","journal-title":"MAbs"},{"key":"2026042115023971300_bib13","doi-asserted-by":"crossref","first-page":"124211","DOI":"10.1016\/j.ijpharm.2024.124211","article-title":"Antibody-Drug Conjugates: a promising breakthrough in cancer therapy","volume":"659","author":"Parit","year":"2024","journal-title":"Int J Pharm"},{"key":"2026042115023971300_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/antib12040072","article-title":"Trends in the development of antibody-drug conjugates for cancer therapy","volume":"12","author":"Song","year":"2023","journal-title":"Antibodies (Basel)"},{"key":"2026042115023971300_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1124\/pr.114.009373","article-title":"Antibody drug conjugates for cancer therapy","volume":"68","author":"Polakis","year":"2016","journal-title":"Pharmacol Rev"},{"key":"2026042115023971300_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11523-025-01140-w","article-title":"Navigating the landscape of resistance mechanisms in antibody-drug conjugates for cancer treatment","volume":"20","author":"Lalli","year":"2025","journal-title":"Target Oncol"},{"key":"2026042115023971300_bib17","first-page":"11","article-title":"Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing","volume":"8","author":"Larose","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"2026042115023971300_bib18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41523-025-00829-5","article-title":"Antibody-drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives","volume":"11","author":"Valle","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"2026042115023971300_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.21037\/tbcr-24-38","article-title":"Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review","volume":"6","author":"Jiang","year":"2025","journal-title":"Transl Breast Cancer Res"},{"key":"2026042115023971300_bib20","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.3390\/cells12192393","article-title":"A CD276-targeted antibody-drug conjugate to treat non-small lung cancer (NSCLC)","volume":"12","author":"Zhang","year":"2023","journal-title":"Cells"},{"key":"2026042115023971300_bib21","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1158\/0008-5472.CAN-23-4099","article-title":"A dual-payload antibody-drug conjugate targeting CD276\/B7-H3 elicits cytotoxicity and immune activation in triple-negative breast cancer","volume":"84","author":"Zhou","year":"2024","journal-title":"Cancer Res"},{"key":"2026042115023971300_bib22","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat Commun"},{"key":"2026042115023971300_bib23","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3390\/pharmaceutics15082020","article-title":"A novel dual-payload ADC for the treatment of HER2+ breast and colon cancer","volume":"15","author":"McKertish","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026042115023971300_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol Cancer"},{"key":"2026042115023971300_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.36401\/JIPO-23-18","article-title":"B7-H3 inhibitors in oncology clinical trials: a review","volume":"7","author":"Feustel","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"2026042115023971300_bib26","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1158\/1078-0432.CCR-16-3107","article-title":"B7-H3 expression in NSCLC and its association with B7-H4, PD-L1 and tumor-infiltrating lymphocytes","volume":"23","author":"Altan","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026042115023971300_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3892\/mmr.2022.12595","article-title":"B7-H3 promotes the epithelial-mesenchymal transition of NSCLC by targeting SIRT1 through the PI3K\/AKT pathway","volume":"25","author":"Liao","year":"2022","journal-title":"Mol Med Rep"},{"key":"2026042115023971300_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2326-6066.CIR-21-0407","article-title":"B7-H3 suppresses antitumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression","volume":"10","author":"Miyamoto","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2026042115023971300_bib29","doi-asserted-by":"crossref","first-page":"16422","DOI":"10.3390\/ijms242216422","article-title":"Regulation of immune checkpoint antigen CD276 (B7-H3) on human placenta-derived mesenchymal stromal cells in GMP-compliant cell culture media","volume":"24","author":"Amend","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026042115023971300_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/ITT.S507522","article-title":"Tumor immunotherapy targeting B7-H3: from mechanisms to clinical applications","volume":"14","author":"Guo","year":"2025","journal-title":"Immunotargets Ther"},{"key":"2026042115023971300_bib31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12885-024-11933-3","article-title":"A promising target for breast cancer: B7-H3","volume":"24","author":"Jiang","year":"2024","journal-title":"BMC Cancer"},{"key":"2026042115023971300_bib32","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.2147\/OTT.S63424","article-title":"B7-H3 expression in breast cancer and upregulation of VEGF through gene silence","volume":"7","author":"Sun","year":"2014","journal-title":"Onco Targets Ther"},{"key":"2026042115023971300_bib33","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1158\/0008-5472.CAN-14-3361","article-title":"Breast cancer detection by B7-H3-targeted ultrasound molecular imaging","volume":"75","author":"Bachawal","year":"2015","journal-title":"Cancer Res"},{"key":"2026042115023971300_bib34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3892\/mmr.2012.1158","article-title":"B7-H3 expression in ductal and lobular breast cancer and its association with IL-10","volume":"7","author":"Liu","year":"2013","journal-title":"Mol Med Rep"},{"key":"2026042115023971300_bib35","first-page":"189","article-title":"Antibody-based therapeutics in small cell lung cancer: a narrative review","volume":"19","author":"Torchia","year":"2025","journal-title":"Biologics"},{"key":"2026042115023971300_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543784.2025.2512566","article-title":"Clinical progress of B7-H3 targeted antibody drug conjugate ifinatamab deruxtecan for small-cell lung cancer","volume":"34","author":"Wespiser","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"2026042115023971300_bib37","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41417-020-0196-5","article-title":"Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy","volume":"28","author":"Si","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"2026042115023971300_bib38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/ph14050427","article-title":"Antibody-drug conjugate to treat meningiomas","volume":"14","author":"Chen","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026042115023971300_bib39","doi-asserted-by":"crossref","first-page":"1663743","DOI":"10.3389\/fonc.2025.1663743","article-title":"Anti-lipolysis-stimulated lipoprotein receptor antibody-drug conjugate to treat triple-negative breast cancer","volume":"15","author":"Zhou","year":"2025","journal-title":"Front Oncol"},{"key":"2026042115023971300_bib40","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1158\/0008-5472.CAN-24-0984","article-title":"mLumiOpto is a mitochondrial-targeted gene therapy for treating cancer","volume":"84","author":"Chen","year":"2024","journal-title":"Cancer Res"},{"key":"2026042115023971300_bib41","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/biomedicines10010130","article-title":"Targeted extracellular vesicles delivered verrucarin A to treat glioblastoma","volume":"10","author":"Chen","year":"2022","journal-title":"Biomedicines"},{"key":"2026042115023971300_bib42","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.3390\/cancers13153749","article-title":"Targeted liposomal chemotherapies to treat triple-negative breast cancer","volume":"13","author":"Si","year":"2021","journal-title":"Cancers"},{"key":"2026042115023971300_bib43","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3390\/pharmaceutics17080967","article-title":"A dual-payload bispecific ADC improved potency and efficacy over single-payload bispecific ADCs","volume":"17","author":"Wilski","year":"2025","journal-title":"Pharmaceutics"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/4\/898\/3775486\/crc-26-0059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/4\/898\/3775486\/crc-26-0059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:02:56Z","timestamp":1776798176000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/4\/898\/783794\/Advanced-CD276-Targeting-Dual-Payload-Antibody"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0059","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32702352","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702385","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702373","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702376","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702364","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702397","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702370","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702391","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702361","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702367","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702388","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702355","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702358","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702346","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32702379","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8542005","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}